Myeloablative conditioning regimens for AML allografts: 30 years later

被引:32
作者
Gupta, V
Lazarus, HM
Keating, A
机构
[1] Princess Margaret Hosp, Ontario Canc Inst, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
关键词
AML; conditioning regimen; busulfan; cyclophosphamide; total body irradiation;
D O I
10.1038/sj.bmt.1704285
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
During the last three decades, several myeloablative conditioning regimens have been used for AML allografts. In this review, we systematically examine the data from studies reporting on myeloablative conditioning regimens for AML allografts. High-dose busulfan combined with cyclophosphamide (BuCy) and cyclophosphamide in combination with total body irradiation (CyTBI) are the two most commonly used conditioning regimens for AML allografts. From the available data, there are no significant differences in survival with these two regimens. A small benefit of decreased relapse rate with CyTBI is counterbalanced by a nonsignificant increase in treatment-related mortality. The incidence of veno-occlusive disease is significantly higher in patients treated with BuCy. Therapeutic monitoring of busulfan was not reported in any of the studies comparing the regimens. Either of the regimens can be used for AML allografts, and the choice may ultimately depend on local availability and expertise. Further improvements may be possible from modi. cations of the standard regimens. Data from these latter studies seem to be encouraging, but are not based on comparative randomized trials.
引用
收藏
页码:969 / 978
页数:10
相关论文
共 86 条
[51]   A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation [J].
Olavarria, E ;
Hassan, M ;
Eades, A ;
Nilsson, C ;
Timms, A ;
Matthews, J ;
Craddock, C ;
Kanfer, E ;
Apperley, J ;
Goldman, J .
LEUKEMIA, 2000, 14 (11) :1954-1959
[52]   T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease [J].
Papadopoulos, EB ;
Carabasi, MH ;
Castro-Malaspina, H ;
Childs, BH ;
Mackinnon, S ;
Boulad, F ;
Gillio, AP ;
Kernan, NA ;
Small, TN ;
Szabolcs, P ;
Taylor, J ;
Yahalom, J ;
Collins, NH ;
Bleau, SA ;
Black, PM ;
Heller, G ;
O'Reilly, RJ ;
Young, JW .
BLOOD, 1998, 91 (03) :1083-1090
[53]   Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ±Ida) and second allogeneic stem cell transplant [J].
Pawson, R ;
Potter, MN ;
Theocharous, P ;
Lawler, M ;
Garg, M ;
Yin, JAL ;
Rezvani, K ;
Craddock, C ;
Rassam, S ;
Prentice, HG .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :622-629
[54]  
RATANATHARATHORN V, 1992, BONE MARROW TRANSPL, V9, P49
[55]   Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation [J].
Reske, SN ;
Bunjes, D ;
Buchmann, I ;
Seitz, U ;
Glatting, G ;
Neumaier, B ;
Kotzerke, J ;
Buck, A ;
Martin, H ;
Döhner, H ;
Bergmann, L .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) :807-815
[56]   Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation:: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia [J].
Ringdén, O ;
Remberger, M ;
Ruutu, T ;
Nikoskelainen, J ;
Volin, L ;
Vindelov, L ;
Parkkali, T ;
Lenhoff, S ;
Sallerfors, B ;
Mellander, L ;
Ljungman, P ;
Jacobsen, N .
BLOOD, 1999, 93 (07) :2196-2201
[57]   A RANDOMIZED TRIAL COMPARING BUSULFAN WITH TOTAL-BODY IRRADIATION AS CONDITIONING IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA - A REPORT FROM THE NORDIC-BONE-MARROW-TRANSPLANTATION-GROUP [J].
RINGDEN, O ;
RUUTU, T ;
REMBERGER, M ;
NIKOSKELAINEN, J ;
VOLIN, L ;
VINDELOV, L ;
PARKKALI, T ;
LENHOFF, S ;
SALLERFORS, B ;
LJUNGMAN, P ;
MELLANDER, L ;
JACOBSEN, N .
BLOOD, 1994, 83 (09) :2723-2730
[58]   A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia [J].
Ringden, O ;
Labopin, M ;
Tura, S ;
Arcese, W ;
Iriondo, A ;
Zittoun, R ;
Sierra, J ;
Gorin, NC .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (03) :637-645
[59]   Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation:: Study of pharmacokinetics and early clinical outcomes [J].
Russell, JA ;
Tran, HT ;
Quinlan, D ;
Chaudhry, A ;
Duggan, P ;
Brown, C ;
Stewart, D ;
Ruether, JD ;
Morris, D ;
Glück, S ;
Gyonyor, E ;
Andersson, BS .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (09) :468-476
[60]  
SANTOS GW, 1982, SEMIN HEMATOL, V19, P227